Kuros Biosciences (LTS:0RHR) FCF Margin % : 6.77% (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Kuros Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kuros Biosciences's Free Cash Flow for the six months ended in Dec. 2024 was CHF2.96 Mil. Kuros Biosciences's Revenue for the six months ended in Dec. 2024 was CHF43.71 Mil. Therefore, Kuros Biosciences's FCF Margin % for the quarter that ended in Dec. 2024 was 6.77%.

As of today, Kuros Biosciences's current FCF Yield % is 0.26%.

The historical rank and industry rank for Kuros Biosciences's FCF Margin % or its related term are showing as below:

LTS:0RHR' s FCF Margin % Range Over the Past 10 Years
Min: -2294.19 Med: -331.21 Max: 2.68
Current: 2.68

During the past 13 years, the highest FCF Margin % of Kuros Biosciences was 2.68%. The lowest was -2294.19%. And the median was -331.21%.

LTS:0RHR's FCF Margin % is ranked better than
61.23% of 828 companies
in the Medical Devices & Instruments industry
Industry Median: -3.96 vs LTS:0RHR: 2.68

Kuros Biosciences FCF Margin % Historical Data

The historical data trend for Kuros Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences FCF Margin % Chart

Kuros Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-234.19

-42.22

-43.08

-27.32

2.68

Kuros Biosciences Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-11.28	-53.13	-11.28	-2.92	6.77

Competitive Comparison of Kuros Biosciences's FCF Margin %

For the Medical Devices subindustry, Kuros Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kuros Biosciences's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's FCF Margin % falls into.

Save Embed

Kuros Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Kuros Biosciences's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	2.028	/	75.555
	=	2.68 %

Kuros Biosciences's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	2.958	/	43.711
	=	6.77 %

Kuros Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kuros Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (LTS:0RHR) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CSBTF:USA KURNz:UK KURN:Switzerland

Address

Wagistrasse 25, Schlieren, Zurich, CHE, 8952

Website

https://www.kurosbio.com

Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of inventive products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategies.

Kuros Biosciences Headlines

No Headlines